

B1  
cancel  
lines or clones is not substantially diminished, wherein the polypeptide comprises the polypeptide set forth in SEQ ID NO:144.

---

B2  
6. (Amended) A polypeptide according to claim 1, wherein the polypeptide comprises 4-9 consecutive amino acids of SEQ ID NO:144.

---

7. (Amended) A polypeptide according to claim 1, wherein the polypeptide comprises 8-9 consecutive amino acids of SEQ ID NO:144.

---

///  
Please add new claims 46-60 to read as follows:

---

46. (New) The polypeptide of claim 1, wherein said immunogenic portion differs from SEQ ID NO:144 at between 1 and 3 amino acid positions, such that the ability of the polypeptide to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.

B3  
47. (New) A composition comprising any one of the polypeptides of claim 1 or claim 46 in combination with a pharmaceutically acceptable carrier or excipient.

48. (New) An immunogenic composition comprising any one of the polypeptides of claim 1 or claim 46 in combination with a non-specific immune response enhancer.

49. (New) The immunogenic composition according to claim 48 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

50. (New) The composition according to claim 48, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants,

Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

*Aut*  
*Cl* 51. (New) The composition of claim 50, wherein said cytokine is selected from the group consisting of GM-CSF and Flt3-ligand.

52. (New) An isolated polypeptide consisting of an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the polypeptide consists of no more than amino acids 1-249 of WT1 and wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:144.

53. (New) The polypeptide according to claim 52, wherein the polypeptide consists of 9-16 consecutive amino acids of WT1 and comprises SEQ ID NO:144.

*B3* 54. (New) The polypeptide according to claim 52, wherein the polypeptide consists of 9-10 consecutive amino acids of WT1 and comprises SEQ ID NO:144.

55. (New) The polypeptide of claim 52, wherein said immunogenic portion differs from WT1 at between 1 and 3 amino acid positions, such that the ability of the polypeptide to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.

56. (New) A composition comprising any one of the polypeptides of claim 52 or claim 55 in combination with a pharmaceutically acceptable carrier or excipient.

57. (New) An immunogenic composition comprising any one of the polypeptides of claim 52 or claim 55 in combination with a non-specific immune response enhancer.